The trial of the vaccine, known as AZD1222 and being developed by AstraZeneca and scientists at the University of Oxford, was generally safe (fevers and headaches hit the majority but could be controlled), and it saw both antibody and T-cell immune responses. Whether this is enough to create a strong and lasting immunity against SARS-CoV-02, the virus causing COVID-19, remains the bigger question, and longer-term follow-up trials will be needed to confirm this (and are ongoing). Source: Fierce Pharma 20/7/2020